SCHEMBL24437413

SCHEMBL24437413

O=C1C=C(Nc2cc(F)c(F)c(F)c2)C(=O)N1c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ EGFR P00533 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.36
▸ MGLL Q99685 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ GRK5 P34947 1/20 0.33
▸ TYRO3 Q06418 1/20 0.33
▸ DYRK1B Q9Y463 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ KAT2B Q92831 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ CTDSP1 Q9GZU7 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24430013 0.89 MEN1 (0.49) MEN1KMT2AHSP90AA1MGLLALDH1A1
SCHEMBL26205804 0.89 MEN1 (0.49) MEN1KMT2AHSP90AA1MGLLALDH1A1
SCHEMBL24437327 0.85 MEN1 (0.46) MEN1KMT2AALDH1A1KDM4EPOLB
SCHEMBL24430007 0.84 MEN1 (0.50) MEN1KMT2AHSP90AA1ALDH1A1KDM4E
SCHEMBL26205811 0.84 KMT2A (0.50) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL9326699 0.83 MEN1 (0.66) MEN1KMT2AHSP90AA1MGLLALDH1A1
SCHEMBL26205837 0.83 MEN1 (0.44) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL24430115 0.83 MEN1 (0.44) MEN1KMT2AALDH1A1KDM4E
SCHEMBL26205908 0.82 MEN1 (0.48) MEN1KMT2AHSP90AA1MGLLALDH1A1
SCHEMBL24430022 0.82 MEN1 (0.48) MEN1KMT2AHSP90AA1MGLLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
WO-2022109066-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885EGFR 1871/4885
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885EGFR 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback